Chatham Capital Group’s GSK GSK Stock Holding History

Chatham Capital Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-5,080	Closed	-$268K	–	152
2017 Q1	$268K	Buy	5,080 +640	+14%	+$32.5K	0.07%	134
2016 Q4	$214K	Sell	4,440 -302	-6%	-$14.9K	0.06%	136
2016 Q3	$256K	Sell	4,742 -298	-6%	-$16.3K	0.08%	127
2016 Q2	$273K	Sell	5,040 -280	-5%	-$14.8K	0.08%	125
2016 Q1	$270K	Sell	5,320 -1,000	-16%	-$49.8K	0.09%	121
2015 Q4	$319K	Sell	6,320 -8,760	-58%	-$447K	0.1%	114
2015 Q3	$725K	Sell	15,080 -3,360	-18%	-$175K	0.24%	75
2015 Q2	$960K	Sell	18,440 -920	-5%	-$51.8K	0.27%	77
2015 Q1	$1.12M	Buy	19,360 +320	+2%	+$18.3K	0.33%	64
2014 Q4	$1.02M	Buy	+19,040	New	+$1.07M	0.3%	66

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Chatham Capital Group's GSK Position: Q2 2017 in Review

Chatham Capital Group sold out of GSK (GSK) in Q2 2017, closing a stake of 5,080 shares — an estimated $268K sold.

Chatham Capital Group first reported a position in GSK in Q4 2014 and held it in 10 quarters. The position peaked at $1.12M in Q1 2015. 779 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

Chatham Capital Group reported no remaining GSK position as of Q2 2017 after selling out during the quarter.
Chatham Capital Group sold 5,080 GSK shares in Q2 2017, an estimated $268K.
Chatham Capital Group first reported a position in GSK in Q4 2014 and held it in 10 quarters.
Chatham Capital Group's GSK position peaked at $1.12M in Q1 2015.
779 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on Chatham Capital Group's 13F filing for Q2 2017, filed 9 Aug 2017.